The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Subscribe To Our Newsletter & Stay Updated
